TY - JOUR
T1 - Assessment of damage in Takayasu's arteritis
AU - Kermani, Tanaz A.
AU - Sreih, Antoine G.
AU - Cuthbertson, David
AU - Khalidi, Nader A.
AU - Koening, Curry L.
AU - McAlear, Carol A.
AU - McAlear, Carol A.
AU - Monach, Paul A.
AU - Moreland, Larry
AU - Pagnoux, Christian
AU - Rhee, Rennie L.
AU - Seo, Philip
AU - Warrington, Kenneth J.
AU - Merkel, Peter A.
N1 - Publisher Copyright:
© 2024 The Author(s).
PY - 2025/2/1
Y1 - 2025/2/1
N2 - Objectives: To evaluate damage and clinical characteristics associated with damage in Takayasu's arteritis (TAK). Methods: Patients with TAK enrolled in a multicentre, prospective, observational study underwent standardized damage assessment every 6 months using the Vasculitis Damage Index (VDI) and the Large-Vessel Vasculitis Index of Damage (LVVID). Results: The study included 236 patients with TAK: 92% female, 81% Caucasian; median (25th, 75th percentile) disease duration = 2.6 (0.12, 6.9) years. Eighty-four percent had follow-up: median (25th, 75th) duration 4.1 (1.9, 7.5) years. Items of damage were present in 89% on VDI, 87% on LVVID, in the peripheral vascular (76% VDI, 74% LVVID) and cardiac (40% VDI, 45% LVVID) systems. During follow-up, 42% patients had new damage, including major vessel stenosis/arterial occlusion (8%), limb claudication (6%), hypertension (7%), aortic aneurysm (4%) and bypass surgery (4%). Disease-specific damage accounted for >90% of new items. Older age, relapse and longer duration of follow-up were associated with new damage items; a higher proportion of patients without new damage were on MTX (P <0.05). Among 48 patients diagnosed with TAK within 180 days of enrolment, new damage occurred in 31% on VDI and 52% on LVVID. History of relapse was associated with new damage in the entire cohort while in patients with a recent diagnosis, older age at diagnosis was associated with new damage. Conclusion: Damage is present in >80% of patients with TAK even with recent diagnosis and >40% of patients accrue new, mainly disease-specific damage. Therapies for TAK that better control disease activity and prevent damage should be prioritized.
AB - Objectives: To evaluate damage and clinical characteristics associated with damage in Takayasu's arteritis (TAK). Methods: Patients with TAK enrolled in a multicentre, prospective, observational study underwent standardized damage assessment every 6 months using the Vasculitis Damage Index (VDI) and the Large-Vessel Vasculitis Index of Damage (LVVID). Results: The study included 236 patients with TAK: 92% female, 81% Caucasian; median (25th, 75th percentile) disease duration = 2.6 (0.12, 6.9) years. Eighty-four percent had follow-up: median (25th, 75th) duration 4.1 (1.9, 7.5) years. Items of damage were present in 89% on VDI, 87% on LVVID, in the peripheral vascular (76% VDI, 74% LVVID) and cardiac (40% VDI, 45% LVVID) systems. During follow-up, 42% patients had new damage, including major vessel stenosis/arterial occlusion (8%), limb claudication (6%), hypertension (7%), aortic aneurysm (4%) and bypass surgery (4%). Disease-specific damage accounted for >90% of new items. Older age, relapse and longer duration of follow-up were associated with new damage items; a higher proportion of patients without new damage were on MTX (P <0.05). Among 48 patients diagnosed with TAK within 180 days of enrolment, new damage occurred in 31% on VDI and 52% on LVVID. History of relapse was associated with new damage in the entire cohort while in patients with a recent diagnosis, older age at diagnosis was associated with new damage. Conclusion: Damage is present in >80% of patients with TAK even with recent diagnosis and >40% of patients accrue new, mainly disease-specific damage. Therapies for TAK that better control disease activity and prevent damage should be prioritized.
KW - Large-Vessel Vasculitis Index of Damage
KW - Takayasu's arteritis
KW - damage
KW - vasculitis damage index
UR - http://www.scopus.com/inward/record.url?scp=85217031066&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85217031066&partnerID=8YFLogxK
U2 - 10.1093/rheumatology/keae333
DO - 10.1093/rheumatology/keae333
M3 - Article
C2 - 38885370
AN - SCOPUS:85217031066
SN - 1462-0324
VL - 64
SP - 682
EP - 689
JO - Rheumatology
JF - Rheumatology
IS - 2
ER -